search
Back to results

Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis (Injections)

Primary Purpose

Knee Osteoarthritis

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Kenalog with bupivacaine Injection
Sponsored by
Foundation for Orthopaedic Research and Education
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis focused on measuring knee injection, Knee osteoarthritis, corticosteroid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Patients must be 18 years of age and be able to consent for themselves. OA grade Kellgren Lawrence Stage II or III. Diagnosis of primary osteoarthritis. Exclusion Criteria: Patients with other forms of arthritis such as inflammatory arthritis. History of narcotic use for the past 6 months. Kellgren Lawrence arthritis grade 1 or 4. Pregnant women and prisoners.

Sites / Locations

  • Florida Orthopaedic InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Kenalog with 0ml bupivacaine

Kenalog with 4ml bupivacaine

Kenalog with 0.25% bupivacaine

Arm Description

The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0ml of bupivacaine. The patients will be randomized into this group.

The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,4ml of bupivacaine. The patients will be randomized into this group.

The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0.25% of bupivacaine. The patients will be randomized into this group.

Outcomes

Primary Outcome Measures

Injection for Knee Pain
Visual Analogue Scale (VAS)
Injection for Knee Pain
Visual Analogue Scale (VAS)
Injection for Knee Pain
Visual Analogue Scale (VAS)
Injection for Knee Pain
Visual Analogue Scale (VAS)
Injection for Knee Pain
Visual Analogue Scale (VAS)
Injection for Knee Pain
Visual Analogue Scale (VAS)
Injection for Knee Pain
Visual Analogue Scale (VAS)

Secondary Outcome Measures

Assessment of Knee Pain
Global Perceived Improvement
Assessment of Knee Pain
Global Perceived Improvement
Assessment of Knee Pain
Global Perceived Improvement
Assessment of Knee Pain
Global Perceived Improvement

Full Information

First Posted
June 5, 2023
Last Updated
June 13, 2023
Sponsor
Foundation for Orthopaedic Research and Education
Collaborators
Florida Orthopaedic Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05906433
Brief Title
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis
Acronym
Injections
Official Title
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2023 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
June 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Foundation for Orthopaedic Research and Education
Collaborators
Florida Orthopaedic Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate pain relief from corticosteroid injection with and without anesthetic as well as with variable volume of anesthetic. Pain relief will be measured using the VAS pain score at the time of the injection as well as several time points following the injection to capture pain relief longevity. The investigators intend to evaluate how well the patients tolerate corticosteroid mixtures without anesthetic as well as with different volumes of anesthetic. Primary measure will be the time from procedure when postoperative status is considered success (as measured by global perceived improvement score).
Detailed Description
Primary objective is to evaluate pain relief from corticosteroids, Kenalog without anesthetic as well as with different volumes of anesthetic. The investigators will measure the VAS pain score at the time of the injection as well as several time points following the injection. Additionally, the investigators will evaluate how long the injection provided pain relief for the patient. The secondary intend is to evaluate how well the patients tolerate Kenalog mixtures without anesthetic as well as with different volumes of anesthetic by using the VAS pain scale. The investigators hypothesize that patient with lower volume of injection will experience less pain during the procedure and that there will be no statistically significant difference in pain level between the study groups during the study period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis
Keywords
knee injection, Knee osteoarthritis, corticosteroid

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
At screening/baseline, informed consent will be obtained, demographics and medical history will be collected, patient x-ray will be reviewed/KL grade confirmed, narcotic use in last 6 months will be screened using E-FORCSE (Florida Prescription Drug Monitoring Program) database, inclusion and exclusion criteria will be assessed, and patient will be randomized into one of the study groups. We will only include patients who are receiving unilateral knee injections. Further, patient's baseline information on VAS Pain and current medication (analgesic or NSAID) will be collected. VAS Pain will be also collected immediately after the intervention and 2 minutes after the intervention, in addition to global perceived improvement score and AEs. The intervention in this study is intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic (0ml, 2ml or 4 ml of 0.25% bupivacaine).
Masking
Participant
Masking Description
The PI standard of care is to offer patients who complain of knee pain a corticosteroids injection regardless of patient participation in a study. A consent will be obtained prior the injection by a trained/qualified team member. Subjects will be randomly allocated to groups by concealed allocation. Randomization sequence between three groups will be created using Excel and will be further stratified by sex within each block, to ensure even distribution. A set of numbered envelopes will be created, with each having one unique group assigned. A staff member will assign an envelope with group assignment upon consent and record envelope number ID. The ARNP will open an envelope, administer injection based on the group assigned. The ARNP will prepare the medication to maintain the double blinded aspect of the study. The ARNP is trained and experienced with injections and has giving injections for several years. She will not be involved in the evaluations of the patient pre/post injection.
Allocation
Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Kenalog with 0ml bupivacaine
Arm Type
Experimental
Arm Description
The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0ml of bupivacaine. The patients will be randomized into this group.
Arm Title
Kenalog with 4ml bupivacaine
Arm Type
Experimental
Arm Description
The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,4ml of bupivacaine. The patients will be randomized into this group.
Arm Title
Kenalog with 0.25% bupivacaine
Arm Type
Experimental
Arm Description
The intervention in this study is one intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic,0.25% of bupivacaine. The patients will be randomized into this group.
Intervention Type
Drug
Intervention Name(s)
Kenalog with bupivacaine Injection
Other Intervention Name(s)
Knee Injection, Corticosteroid Injection, Kenalog, Bupivacaine
Intervention Description
Indications, relevant for this study include Kenalog injection for knee pain from osteoarthritis or inflammatory arthritis. A single injection to a patient who has no known allergies to anesthetic or corticosteroids would be administered during a scheduled clinical visit.
Primary Outcome Measure Information:
Title
Injection for Knee Pain
Description
Visual Analogue Scale (VAS)
Time Frame
Prior to procedure (in office)
Title
Injection for Knee Pain
Description
Visual Analogue Scale (VAS)
Time Frame
Immediate post procedure (in office)
Title
Injection for Knee Pain
Description
Visual Analogue Scale (VAS)
Time Frame
2 minutes post procedure (in office)
Title
Injection for Knee Pain
Description
Visual Analogue Scale (VAS)
Time Frame
Day 1 post procedure (phone interview)
Title
Injection for Knee Pain
Description
Visual Analogue Scale (VAS)
Time Frame
Day 14 post procedure (through EDC)
Title
Injection for Knee Pain
Description
Visual Analogue Scale (VAS)
Time Frame
Day 42 post procedure (in office)
Title
Injection for Knee Pain
Description
Visual Analogue Scale (VAS)
Time Frame
Day 84 post procedure (through EDC)
Secondary Outcome Measure Information:
Title
Assessment of Knee Pain
Description
Global Perceived Improvement
Time Frame
Immediate Post-op (in office)
Title
Assessment of Knee Pain
Description
Global Perceived Improvement
Time Frame
Day 1 post procedure (phone interview)
Title
Assessment of Knee Pain
Description
Global Perceived Improvement
Time Frame
Day 42 post procedure (in office)
Title
Assessment of Knee Pain
Description
Global Perceived Improvement
Time Frame
Day 84 post procedure (through EDC)
Other Pre-specified Outcome Measures:
Title
Medications
Description
Review of Medications
Time Frame
Prior to procedure (in office)
Title
Medications
Description
Review of Medications
Time Frame
Day 1 post procedure (phone interview)
Title
Medications
Description
Review of Medications
Time Frame
Day 14 post procedure (through EDC)
Title
Medications
Description
Review of Medications
Time Frame
Day 42 post procedure (in office)
Title
Medications
Description
Review of Medications
Time Frame
Day 84 post procedure (through EDC)
Title
Review of Adverse Events
Description
Any issues with procedure
Time Frame
Immediate post procedure (in office)
Title
Review of Adverse Events
Description
Any issues with procedure
Time Frame
Day 1 post procedure (phone interview)
Title
Review of Adverse Events
Description
Any issues with procedure
Time Frame
Day 42 post procedure (in office)
Title
Review of Adverse Events
Description
Any issues with procedure
Time Frame
Day 84 post procedure (through EDC)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients must be 18 years of age and be able to consent for themselves. OA grade Kellgren Lawrence Stage II or III. Diagnosis of primary osteoarthritis. Exclusion Criteria: Patients with other forms of arthritis such as inflammatory arthritis. History of narcotic use for the past 6 months. Kellgren Lawrence arthritis grade 1 or 4. Pregnant women and prisoners.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sherri Leverett, CRC
Phone
(813)910-3690
Email
Sleverett@foreonline.org
First Name & Middle Initial & Last Name or Official Title & Degree
Kathy Kops, CRC
Phone
(813)910-3689
Email
kkops@foreonline.org
Facility Information:
Facility Name
Florida Orthopaedic Institute
City
Tampa
State/Province
Florida
ZIP/Postal Code
33637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brian T Palumbo, MD
Phone
813-978-9700
Email
bpalumbo@floridaortho.com
First Name & Middle Initial & Last Name & Degree
Thomas T Bernasek, MD
Phone
(813)978-9700
Email
Tbernasek@floridaortho.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29079170
Citation
Bedard NA, Dowdle SB, Anthony CA, DeMik DE, McHugh MA, Bozic KJ, Callaghan JJ. Response to Letter to the Editor on "The AAHKS Clinical Research Award: What Are the Costs of Knee Osteoarthritis in the Year Prior to Total Knee Arthroplasty?". J Arthroplasty. 2018 Jan;33(1):307. doi: 10.1016/j.arth.2017.10.002. Epub 2017 Oct 10. No abstract available.
Results Reference
background
PubMed Identifier
33616067
Citation
Blankstein M, Lentine B, Nelms NJ. Common Practices in Intra-Articular Corticosteroid Injection for the Treatment of Knee Osteoarthritis: A Survey of the American Association of Hip and Knee Surgeons Membership. J Arthroplasty. 2021 Mar;36(3):845-850. doi: 10.1016/j.arth.2020.09.022. Epub 2020 Oct 8.
Results Reference
background
PubMed Identifier
20194319
Citation
Grishko V, Xu M, Wilson G, Pearsall AW 4th. Apoptosis and mitochondrial dysfunction in human chondrocytes following exposure to lidocaine, bupivacaine, and ropivacaine. J Bone Joint Surg Am. 2010 Mar;92(3):609-18. doi: 10.2106/JBJS.H.01847.
Results Reference
background
PubMed Identifier
12867587
Citation
Smith MD, Wetherall M, Darby T, Esterman A, Slavotinek J, Roberts-Thomson P, Coleman M, Ahern MJ. A randomized placebo-controlled trial of arthroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee. Rheumatology (Oxford). 2003 Dec;42(12):1477-85. doi: 10.1093/rheumatology/keg398. Epub 2003 Jul 16.
Results Reference
background
PubMed Identifier
17244900
Citation
Parker RD, Streem K, Schmitz L, Martineau PA; Marguerite Group. Efficacy of continuous intra-articular bupivacaine infusion for postoperative analgesia after anterior cruciate ligament reconstruction: a double-blinded, placebo-controlled, prospective, and randomized study. Am J Sports Med. 2007 Apr;35(4):531-6. doi: 10.1177/0363546506296313. Epub 2007 Jan 23.
Results Reference
background

Learn more about this trial

Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis

We'll reach out to this number within 24 hrs